IFNA1 and insomnia measurement: Within thirty days of hospitalization with COVID-19 and Type I IFN treatment, the cohort of interest had approximately the same odds as the comparison cohort of having nerve, nerve root, and plexus disorders (OR [95% CI]: 0.98 [0.40, 2.40]), substance use disorders (OR [95% CI]: 1.01 [0.41, 2.48]), psychotic, mood, and anxiety disorders (OR [95% CI]: 0.94 [0.38, 2.30]), and insomnia (OR [95% CI]: 1.05 [0.43, 2.57]).